Results 261 to 270 of about 44,321 (338)

Successful targeting of multidrug-resistant tumors with bispecific antibodies. [PDF]

MAbs
Briante R, Zhai Q, Mohanty S, Zhang P, O'Connor A, Misker H, Wang W, Tan C, Abuhay M, Morgan J, Theolis R, Ponath P, Arathoon R.   +12 more
europepmc   +1 more source

Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study

HemaSphere, Volume 10, Issue 1, January 2026.
ABSTRACT Novel therapies are needed for patients with multiple myeloma (MM) and extramedullary plasmacytomas. The prospective, Phase II EMN19 study assessed the efficacy and safety of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone (DaraVCD) in 40 patients with newly diagnosed MM (NDMM; n = 29) or at first relapse (RMM; n = 11) and ...
Meral Beksac, Tulin Fıratlı Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H. J. van der Velden, Berna H. Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz Seval, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Peter Sonneveld, Elena Zamagni, Evangelos Terpos   +18 more
wiley   +1 more source

High-affinity transferrin receptor binding improves brain delivery of bispecific antibodies at tracer dose. [PDF]

Fluids Barriers CNS
Bonvicini G, Singh S, Sandersjöö L, Dallas T, Schlein E, Dahlén AD, Lopes van den Broek S, Sehlin D, Andersson KG, Syvänen S.   +9 more
europepmc   +1 more source

Bispecific FpFs: a versatile tool for preclinical antibody development

Matthew Collins, Nkiruka Ibeanu, Wiktoria Roksana Grabowska, Sahar Awwad, Peng T. Khaw, Steve Brocchini, Hanieh Khalili   +6 more
openalex   +2 more sources

Triplet regimens for frontline treatment of CLL—Great company or just a crowd?

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Standard frontline treatment of chronic lymphocytic leukemia (CLL) is with fixed‐duration venetoclax‐based doublets or indefinite covalent Bruton tyrosine kinase inhibitor (BTKI). Although these approaches achieve excellent results, venetoclax doublets have diminished efficacy in high‐risk biological subgroups, and indefinite covalent Bruton ...
Sean McKeague, John F. Seymour
wiley   +1 more source

Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities. [PDF]

Explor Target Antitumor Ther
Parola S, Colombo I.
europepmc   +1 more source

Hematopoietic progenitor kinase-1 inhibition improves the in vitro efficacy of bispecific antibodies in CLL. [PDF]

Blood Adv
Shorer Arbel Y, Yitzhak L, Katz BZ, Herishanu Y.   +3 more
europepmc   +1 more source

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT The optimal second‐line chemotherapy regimen for relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) remains uncertain. We retrospectively compared efficacy and safety between gemcitabine, carboplatin, dexamethasone, and rituximab (GCD‐R) and cyclophosphamide, high‐dose cytarabine, dexamethasone, etoposide, and rituximab (CHASER ...
Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Naoki Hayase, Eri Takada, Takuro Matsumoto, Yuhei Shibata, Hiroshi Nakamura, Kei Fujita, Shin Lee, Tetsuji Morishita, Nobuhiro Kanemura, Senji Kasahara, Hideko Goto, Kenji Fukuno, Takeshi Hara, Michio Sawada, Hisashi Tsurumi, Masahito Shimizu   +18 more
wiley   +1 more source

Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma. [PDF]

Blood Cancer J
Golmohammadi M, Raza S, Albayyadhi M, Sholehrasa H, Khouri J, Williams L, Hansen DK, Moradi A, Xu X, Albliwi M, Ali AH, Dima D, Anwer F, Paul B, Jaberi-Douraki M.   +14 more
europepmc   +1 more source

Single-domain antibodies for brain targeting [PDF]

, 2014
Lalatsa, Katerina, Moreira Leite, Diana
core   +1 more source